Health Care • Biotechnology: Pharmaceutical Preparations
$1.63 ▲ +0.03
(+1.61%)
MKT CAP: $8.9M • VOL: 37.4K
52W L $1 52W H $2
ROARABLE / RQD
D • 47/100
PIOTROSKI
4 / 9
INM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $4.9M | $4.6M | $4.1M |
| YoY Revenue Growth % | +7.5% | +11.2% | — |
| Gross Profit | $1.7M | $1.1M | — |
| Gross Margin % | 34.5% | 23.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $0 | $0 | -$7.9M |
| Operating Margin % | — | — | -80.0% |
| Net Income (GAAP) | -$8.2M | -$7.7M | -$7.9M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$8.1M | -$7.0M | -$7.3M |
| Capital Expenditures (CapEx) | $0 | $9.3K | — |
| Free Cash Flow (FCF) | -$8.1M | -$7.0M | -$7.3M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | — | — | — |
| Cash & Short-Term Equivalents | $7.0M | $3.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $9.6M | $6.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR INM.